Theresa A. Deisher, PhD.
Dr. Deisher is a world renowned scientist in the field of adult stem cell therapies and regenerative medicine with over 20 years of experience. Dr. Deisher has 23 patents in her name, which have generated more than $100 million in licensing revenue and entail more than $100 million more in possible future royalty payments. Several more of her inventions are currently in clinical trials.
Prior to founding AVM, Dr. Deisher’s previous assignments included Vice President at Cellcyte Genetics (Kirkland, WA); Principal Scientist at Amgen (Seattle, WA); Sr. Staff Scientist, Vascular Biology at Immunex (Seattle, WA); Sr. Scientist, Cardiovascular Biology at ZymoGenetics (Seattle, WA); and, Research Scientist at Repligen (Waltham, MA). She was the first person world-wide to identify and patent stem cells from the adult heart, including what are now called “very small embryonic-like stem cells” (VSELS), and also is a patented inventor of the most potent mesenchymal growth factor ever identified, as well as of the use of cytokines to mobilize adult embryonic-like cells.
Dr. Deisher graduated with honors and distinction from Stanford University, and obtained her Ph.D. in Molecular and Cellular Physiology from Stanford University.
Dr. Deisher is concurrently President of Sound Choice Pharmaceutical Institute, a non-profit affiliate of the Company.